This summary was created by AI, based on 1 opinions in the last 12 months.
Elanco Animal Health, with symbol ELAN-N, was spun off from Eli Lilly in 2018. Their recent report showed a mixed performance, with their pet business missing guidance for the current quarter, but they are taking steps to address this by selling their Aqua business to Merck Animal Health, announcing restructuring and job cuts, and planning to increase cash flow conversions. Experts have a cautious but hopeful outlook for the company.
Spun off from Eli Lilly in 2018. Reported a mixed report today, including their pet business missing as guidance for the current quarter fell short. They will sell its Aqua business to Merck Animal Health, announced restructuring/job cuts and will increase cash flow conversions four times this year, which is a priority. This gives him some hope in the name.
Elanco Animal Health is a American stock, trading under the symbol ELAN-N on the New York Stock Exchange (ELAN). It is usually referred to as NYSE:ELAN or ELAN-N
In the last year, 2 stock analysts published opinions about ELAN-N. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Elanco Animal Health.
Elanco Animal Health was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Elanco Animal Health.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Elanco Animal Health published on Stockchase.
On 2024-08-30, Elanco Animal Health (ELAN-N) stock closed at a price of $15.47.
Is up 17% in August. It's all about animal health, an enormous industry. They have a fine product pipeline, and all products' revenues have climbed from $350-400 million to $450 million. Cheap at 14x PE and 1x book.